Press coverage about Zosano Pharma Corporation (NASDAQ:ZSAN) has been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Zosano Pharma Corporation earned a coverage optimism score of 0.22 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.8808836201988 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:

Separately, ValuEngine downgraded Zosano Pharma Corporation from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $2.58.

Shares of Zosano Pharma Corporation (NASDAQ:ZSAN) traded down 2.80% on Tuesday, reaching $1.04. The company’s stock had a trading volume of 630,237 shares. The stock has a 50-day moving average of $1.33 and a 200 day moving average of $1.58. Zosano Pharma Corporation has a 52-week low of $0.45 and a 52-week high of $3.54. The company’s market cap is $40.77 million.

Zosano Pharma Corporation (NASDAQ:ZSAN) last posted its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.04. On average, equities research analysts forecast that Zosano Pharma Corporation will post ($0.97) earnings per share for the current year.

In other news, CEO John Peter Walker acquired 73,716 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The stock was bought at an average price of $1.36 per share, with a total value of $100,253.76. Following the completion of the acquisition, the chief executive officer now directly owns 169,344 shares of the company’s stock, valued at approximately $230,307.84. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Georgia Erbez acquired 68,000 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The stock was purchased at an average cost of $1.32 per share, with a total value of $89,760.00. Following the acquisition, the chief financial officer now directly owns 115,750 shares of the company’s stock, valued at $152,790. The disclosure for this purchase can be found here. 2.95% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Zosano Pharma Corporation (ZSAN) Getting Somewhat Positive Media Coverage, Study Shows” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at

Zosano Pharma Corporation Company Profile

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

Insider Buying and Selling by Quarter for Zosano Pharma Corporation (NASDAQ:ZSAN)

Receive News & Ratings for Zosano Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corporation and related companies with's FREE daily email newsletter.